Genetic predictors of response to specific drugs in primary myelofibrosis
Primary myelofibrosis (PMF) constitutes clonal expansion of myeloid cells and is characterized by "driver" (i.e., JAK2, CALR, and MPL) and other mutations or DNA variants, such as ASXL1, TET2, SRSF2, IDH1, IDH2, and U2AF1 [1] [2] [3] . Patients with PMF have an estimated median survival of 6 years and causes of death include leukemic transformation; in addition, quality of life is markedly impaired in PMF as result of frequent red blood cell transfusion requirement, markedly enlarged spleen and severe constitutional symptoms 4, 5 . At present allogeneic stem cell transplant (ASCT) is the only treatment modality with potential to either cure the disease or prolong survival of patients with PMF, while current drug therapy offers palliative value only (e.g., reduction in spleen size, reduction of constitutional symptoms, and improvement in anemia) 6, 7 . In this regard, hydroxyurea (HU), JAK2 inhibitors, and interferon (IFN)-α are often used for symptomatic splenomegaly: JAK2 inhibitors for constitutional symptoms and immunomodulatory drugs (IMiDs), erythropoiesis-stimulating agents (ESAs), and androgens for anemia 8 . The current study was approved by the Mayo Clinic Institutional Review Board (IRB) and represents a retrospective evaluation of specific drug response, in terms of anemia or splenomegaly, in patients with PMF receiving these agents as first-line treatment. Diagnoses and treatment approaches were in accordance with what was considered standard of care at the time of initial diagnosis or first referral 9 . Study patients were recruited from the Mayo Clinic, Rochester, MN, USA. Diagnoses were according to the 2016 World Health Organization criteria 10 . To ascertain the role of genetic biomarkers, study inclusion criteria included availability of karyotype and next-generation sequencing (NGS)-derived mutation information.
Variables evaluated included those that are currently listed in MIPSS70 (mutation-enhanced international prognostic scoring system for transplant-age patients), MIPSS70 + version 2.0 (karyotype-enhanced MIPSS70), and GIPSS (genetically-inspired prognostic scoring system) [11] [12] [13] . For the purposes of the current study, conventional response criteria were modified to reflect clinical benefit assessment without strict adherence to criteria designed for clinical trials. Accordingly, spleen response was evaluated only in patients with palpable splenomegaly and was defined as a minimum 50% reduction in palpable spleen size, regardless of response duration. Anemia response was evaluated only in patients with hemoglobin level < 10 g/dl and was defined as achieving transfusion-independence lasting for at least 1 month or an increase in hemoglobin of 2 g/dl, regardless of response duration 14 . Statistical analyses considered clinical and laboratory parameters obtained at time of diagnosis or first referral, which coincided, in all instances, with time of sample collection for mutation analysis. Conventional methods were used for statistical analysis (JMP® Pro 13.0.0 software; SAS Institute, Cary, NC).
A total of 432 cytogenetically-and molecularlyannotated patients with PMF were accessed (Supplementary Table 1 ) in order to identify 333 patients who received first-line treatment with HU (n = 97), JAK2 inhibitors (n = 41), IFN-α (n = 22), IMiDs (n = 58), androgens (n = 19), ESAs (n = 54), and various other drugs (n = 42), and were evaluable for response. Presenting features of the 333 study patients (median age 64 years; 68% males) included palpable splenomegaly (77%), Table 1 Predictors of spleen response to specific drugs in patients with primary myelofibrosis receiving these agents as (28) 32 (80) 22 (69) 
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